Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

The hope is that approach will kill tumour cells but avoid off-target side effects, such as the potentially ... partnered PD-1 checkpoint inhibitor Libtayo (cemiplimab), and the drugmaker has ...

However, CAR-Ts are made from patients’ cells and have complex manufacturing and administration procedures, are associated with higher rates of side effects, such as cytokine release syndrome ...

Common risks or side effects of a biopsy procedure that is used to obtain ... pembrolizumab (Keytruda®), atezolizumab (Tecentriq®), and cemiplimab (Libtayo®). Of note, these pharmacological agents ...

THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

It's not uncommon to experience side effects in the first few weeks of taking a new antidepressant. Here's what to look out ...

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

A “mycology thriller” imagines a hidden healing mushroom. In real life, scientists are searching far and wide to map the world’s unseen fungi.

A ~$4.5B share repurchase program adds further value. LIBTAYO demonstrated massive growth, accelerating to 50% in Q4 2024 versus Q4 2023. Approval in CSCC means that this growth catalyst is ...

Built from contrasts as delightful as they are disconcerting, the new animated series from folks behind "Scavengers Reign" ...

Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.